Gilead Sciences, Inc. (GILD) Announces Updated Phase 2 Results For Investigational GS-9973 In Relapsed Chronic Lymphocytic Leukemia
6/3/2014 9:26:31 AM
CHICAGO--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) today announced updated interim results of a Phase 2 study (Study 102) evaluating GS-9973, its investigational oral inhibitor of spleen tyrosine kinase (Syk), for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL). In this study, single-agent treatment with GS-9973 achieved an overall response rate of 49 percent, with an estimated progression-free survival (PFS) rate at 24 weeks of 70 percent. Detailed results will be presented today during an oral session at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago (Abstract #7007).
Help employers find you! Check out all the jobs and post your resume.
comments powered by